Advertisement

Topics

Gilead patent cliff looms as Teva plans generic Truvada launch

04:34 EDT 13 May 2019 | pharmaphorum

Gilead’s HIV blockbuster Truvada looks set to face generic competition in the US next year, a year earlier than expected, putting the bulk of the product’s $3 billion annual sales at risk. The US company had been predicting the onset of generic co...

Original Article: Gilead patent cliff looms as Teva plans generic Truvada launch

NEXT ARTICLE

More From BioPortfolio on "Gilead patent cliff looms as Teva plans generic Truvada launch"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...